Reporting to the Director, Field Medical Affairs, the Medical Science Director (MSD) is a remote employee that helps drive success of Audentes gene therapy programs by engaging and developing relationships with key decision-makers and medical experts to: 1) facilitate program success by uncovering where patients are being treated, understanding the diagnostic and treatment journey for patients, educating physicians about gene therapy and our clinical trials, identifying potential clinical trial and referral centers and partnering cross-functionally to successfully execute clinical trials, and developing and executing territory specific medical strategy to support clinical and commercial stages, 2) conduct fair and balanced scientific exchange with health care practitioners in clinics and at medical congresses, including capturing clinical and scientific insights to help inform clinical development programs and gather information about the competitive landscape.
The Field Medical Affairs team is critical at this exciting stage for our company as we continue to bring innovative gene therapy science into clinical trials for patients with severe, rare diseases with an unmet need. MSDs, as the global field medical face of Audentes, are essential to collaborating with, and incorporating the perspective of, external experts in our development programs.
The open position is for United States - Southeast and will cover the southeastern part of the country, and contribute to our growing global Field Medical Affairs organization.
Specific responsibilities include but are not limited to:
Required Education, Skills and Experience
Preferred Skills and Experience
|Posted on||23 Jan 2019|
Audentes Therapeutics (NASDAQ: BOLD) is a biotechnology company committed to the development and commercialization of innovative gene therapy products for patients living with serious, life-threatening rare diseases. We believe gene therapy technology has tremendous potential as a treatment approach for many genetic diseases. We are currently conducting Phase 1/2 clinical studies of our lead product candidates, AT132 for the treatment of X-linked Myotubular Myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar syndrome. We have two additional product candidates in development, including AT845 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). We are a focused, experienced and passionate team driven by the goal of improving the lives of patients.
Audentes takes pride in strong, global relationships with the patient, research and medical communities, and we take equal pride in carefully selecting our colleagues. If you believe you match what we're looking for, we'd love to hear from you. Our compensation philosophy embodies what you'd expect from an innovative life sciences employer competing for the best talent available.
Listed below is a current opening for which we are seeking smart, driven, experienced, and just plain nice people to join us in realizing Audentes' mission.